What Three Health Notifications Taught Me About Alzheimer’s Risk

TL;DR

Before you orderOffer from Amazon

Get health and wellness essentials delivered free with Prime

• Fast, free delivery on millions of items
• Prime Video, Amazon Music and more included
• Member-only deals all year

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

In a first-person report published by Being Patient on October 6, 2026, Ron Carr recounts three health notifications that changed how he thought about Alzheimer’s risk and prevention. The supplied report details an APOE4 genetic result and a coronary calcium scan showing plaque; it does not include the third notification or establish that any intervention prevents Alzheimer’s.

Being Patient published a first-person account on October 6, 2026, in which patient advocate Ron Carr describes how an APOE4 genetic result and a coronary artery calcium scan changed his understanding of health risks tied to Alzheimer’s disease. The available report recounts two notifications, including evidence of coronary plaque; despite its title referring to three, the supplied text does not describe the third.

Carr writes that a genetic test two years earlier showed he carries two copies of APOE4, a gene variant associated with increased risk of late-onset Alzheimer’s disease. He initially experienced the result as a prediction, he says, becoming anxious about ordinary lapses such as forgetting names or misplacing keys. He describes responding by closely following research and repeatedly changing his diet, exercise routine and supplement use.

He later came to understand that APOE4 is a risk factor, not a diagnosis, according to his account. Carr says that distinction helped him shift from treating the result as a fixed forecast to thinking about health choices. The essay does not provide clinical evidence that his particular dietary changes or supplements reduce Alzheimer’s risk.

The second notification came after a clinician at the University of Southern California discussed APOE4’s role in lipid transport and Carr underwent a coronary artery calcium scan. Carr reports that the scan showed substantial calcified plaque, concentrated largely in his left anterior descending artery. At age 65, he says, he was diagnosed with atherosclerotic cardiovascular disease. His clinician then lowered his LDL cholesterol and ApoB targets and adjusted his treatment; follow-up testing, Carr writes, showed no structural heart damage.

How Risk Information Changed His Care

Carr’s account illustrates how a genetic result can prompt someone to seek more information, and how a test ordered in response to that information can reveal a separate health condition. In his case, the scan changed the conversation from future risk to diagnosed cardiovascular disease, leading his clinician to revise treatment. The essay is a patient’s account, not a clinical study, and it cannot show that this sequence is appropriate for everyone.

For readers, the distinction between risk and diagnosis is central. A genetic risk marker does not establish that a person has Alzheimer’s or will develop it. Similarly, Carr’s reported scan findings and treatment decisions are specific to his medical history. Whether genetic testing, imaging or a particular prevention plan makes sense depends on individual circumstances and a discussion with a qualified clinician.

From Genetic Result to Heart Scan

The report places Carr’s experience against a family history of cardiovascular disease: he writes that his father had a heart attack at 65 and survived, but his life became more limited afterward. Carr says he had long exercised, followed a heart-conscious diet and eventually accepted statin therapy. His cholesterol had been considered acceptable by his physician before the scan revealed plaque.

Carr also refers to the Lancet Commission’s estimate that up to 45% of dementia cases may be attributable to potentially modifiable risk factors. That figure is an estimate about population-level risk factors; it does not mean that 45% of cases can certainly be prevented, nor does it predict an individual’s outcome. The report identifies Carr as a retired local government executive and patient advocate who has shared his perspective through USC’s Center for Personalized Brain Health and the Family Heart Foundation.

“APOE4 is not a diagnosis. It is a risk factor.”

— Ron Carr, in his Being Patient account

The Missing Third Notification

The supplied excerpt stops during Carr’s account of the second notification and does not identify the third notification promised by the title. Its nature, timing and implications therefore cannot be reported from the material provided. The excerpt also does not include the scan’s numerical score, detailed treatment regimen or the outcome of any longer-term follow-up.

More broadly, the account does not establish that APOE4 testing or coronary calcium imaging should be used routinely to assess Alzheimer’s risk. It offers one person’s experience and his account of discussions with clinicians. The source material does not provide a clinician’s independent comment, research findings specific to Carr, or evidence that his changes in diet, exercise or medication prevent dementia.

Further Details Needed on Notification Three

The next step for a complete account is the remaining portion of Carr’s published essay, which is not included in the supplied text. Until that information is available, the third notification and what Carr learned from it remain unconfirmed here. Readers seeking to understand their own genetic or cardiovascular risks should discuss testing and results with a qualified health professional; Carr’s experience alone cannot determine an appropriate course of care.

Key Questions

What did Carr learn from his genetic test?

Carr says the test showed he carries two copies of APOE4, a genetic risk factor associated with late-onset Alzheimer’s. He emphasizes that the result is not itself an Alzheimer’s diagnosis.

What did the coronary calcium scan show?

Carr reports that the scan showed substantial calcified plaque, mostly in his left anterior descending artery. He says he was diagnosed with atherosclerotic cardiovascular disease at age 65. The supplied account does not state his scan score.

Does the report say Carr’s lifestyle changes prevent Alzheimer’s?

No. The account describes changes Carr made and how he thought about risk, but it does not establish that his diet, supplements or exercise plan prevents Alzheimer’s. The source’s cited estimate about modifiable risk factors concerns population-level dementia cases, not a guaranteed individual outcome.

What was the third health notification?

The supplied excerpt does not say. It ends while describing the consequences of Carr’s heart scan, so the third notification cannot be identified from the provided material.

Source: rss